Dr. Phillip Phillip Joins Henry Ford Cancer Institute in Leadership Roles

Dr. Phillip Phillip headshot
Courtesy of Henry Ford Health System

Dr. Phillip Phillip, an internationally renowned medical oncologist, has joined Henry Ford Cancer Institute (HFCI) in Detroit as director of gastrointestinal oncology and neuroendocrine oncology, medical director of research and clinical care integration, and co-leader of the Henry Ford Pancreatic Cancer Center.

“Dr. Philip is a prolific researcher and skillful clinician with extensive experience in an academic medical center environment,” says Dr. Steven Kalkanis, CEO of the Henry Ford Medical Group and chief academic officer at Henry Ford Health System.

“He is a strong leader with a proven track record demonstrating his deep commitment to providing outstanding patient care and achieving scientific breakthroughs that are continuing to help advance research in many aspects of pancreatic cancer. We are thrilled to have Dr. Philip joining our Henry Ford Cancer Institute as we launch into the next generation of both patient care and clinical research.”

Phillip has led numerous breakthroughs over the course of his career in the areas of pancreatic cancer and neuroendocrine tumors. He joins HFCI from Karmanos Cancer Institute where he served in numerous leadership roles during the past 25 years. He will continue to serve as a tenured professor of oncology at Wayne State University School of Medicine.

“Dr. Philip’s wide-ranging expertise on both the national and international cancer research stages will be an invaluable addition to our Henry Ford Cancer Institute as we continue to pursue discoveries that will increase survivorship among patients with pancreatic cancer,” says Dr. Benjamin Movsas, interim medical director of HFCI.

“By leveraging our advanced research and clinical capabilities, we remain committed to reducing disparities in cancer outcomes and staying on the forefront of scientific research that will help save lives.”

Philip received his medical degree from the University of Baghdad, College of Medicine, and his doctorate in clinical pharmacology and pharmacogenetics from the University of London Guy’s Hospital Medical School. He completed a residency at the University of Baghdad. He completed fellowship in medical oncology at the University of Oxford in London and at MD Anderson Cancer Center in Houston.